查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853734

呼吸道感染疾病诊断市场按技术、样本类型、检测方式、感染类型和最终用户划分－全球预测，2025-2032年

Respiratory Infection Diagnostics Market by Technology, Sample Type, Test Mode, Infection Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，呼吸道感染疾病诊断市场规模将达到 1,454.4 亿美元，复合年增长率为 7.36%。

关键市场统计数据
基准年 2024 823.5亿美元
预计年份：2025年 883.8亿美元
预测年份 2032 1454.4亿美元
复合年增长率 (%) 7.36%

本文简要介绍了临床压力、技术进步和不断变化的诊疗路径如何重新定义呼吸道感染疾病的诊断重点。

呼吸道感染疾病诊断在临床护理、公共卫生和实验室创新之间发挥核心作用。分子检测、照护现场设备和数据整合技术的进步缩短了诊断週期，并将检测范围从中心实验室扩展到医院、诊所和居家医疗。同时，近期疫情的爆发促使人们更加重视疾病监测，这促使支付方、医疗服务提供者和公共卫生机构重新评估诊断路径及其在疫情防治和日常实践中的作用。

临床医生日益要求诊断方法能够在临床相关的时间范围内提供可操作的结果，而实验室技术人员则优先考虑自动化和可重复性，以应对不断波动的检测量。製造商和解决方案供应商正透过整合平台、模组化耗材和软体驱动的工作流程来应对这些需求，从而弥合实验室检测精度与即时检测之间的差距。因此，策略性相关人员必须应对不断变化的法律规范、供应链压力和报销预期，才能将技术能力转化为持续的临床应用。

技术、监管和数位化趋势如何加速呼吸道感染疾病诊断解决方案的成熟和临床应用

呼吸道感染疾病诊断正经历多重变革，重塑产品开发、筹资策略和临床工作流程。分子检测已从高复杂度的实验室检测发展为精简的床边检测平台，显着缩短了检测结果的获取时间，并增强了针对特定病原体的管理。同时，定序技术也从专业研究工具转变为可操作的临床资源，能够进行菌株鑑定和抗药性监测，从而为治疗和公共卫生应对措施提供资讯。

自动化和整合式样本到结果系统正在降低对操作人员的依赖性，并支援医院实验室实现可扩展的检测通量；同时，侧向层析免疫测量和其他快速检测方法不断扩大分散式检查的覆盖范围。主导的解读和云端资料聚合正开始将侦测结果与流行病学资讯连结起来，有助于及早发现新出现的丛集。监管机构也在不断发展，日益支持紧急使用途径和加速审查机制，同时强调上市后性能监测。这些转变正在建立多模态诊断生态系统，其中商业性成功取决于互通性、资料完整性和供应链的稳定性。

评估新的关税结构将如何重塑供应链、驱动筹资策略以及影响诊断试剂製造商和供应商的采购行为。

美国将于2025年实施累积关税，这将对呼吸诊断产品的上游生产和下游临床供应产生一系列复杂的压力。进口零件和成品设备关税的提高可能会增加依赖全球供应链获取关键试剂、塑胶、墨盒和精密仪器组件的製造商的单位成本。这些成本压力可能会挤压製造商的利润空间，促使他们重新谈判供应商合同，并推动产品重新设计，优先考虑国内采购和零件标准化，以减轻关税的影响。

对于临床实验室和即时检测 (POC) 服务提供者而言，关税导致的成本增加可能表现为设备购买价格上涨和耗材的持续支出增加。为因应此问题，采购团队可能会延长设备更换週期、整合供应商，或优先选择可降低单次诊断耗材消费量的多重侦测方法。同时，一些製造商可能会加快本地化生产或对替代供应商进行资格认证的策略步伐。这个过程虽然提高了供应的稳定性，但由于资格认证和监管检验的要求，也可能延长产品上市时间。

政策变化也将影响诊断研发公司的资本配置决策。投资者和企业决策者可能会重新评估其生产布局，并考虑与契约製造製造商采用联合投资模式，以分散关税风险。公共机构负责人和医院网路可以利用其购买力，协商分级定价和长期供应协议，从而稳定下游成本。最终，关税环境凸显了供应链透明度、组件可追溯性和灵活筹资策略的重要性，这些策略需要在短期成本影响与长期可靠性和临床连续性之间取得平衡。

详细的细分洞察揭示了技术、样本类型、检测模式、感染重点和最终用户动态如何独特地塑造产品需求和采用路径。

详细的市场区隔分析揭示了不同技术和应用场景如何推动差异化的应用和创新。从技术角度来看，酵素结合免疫吸附检测法（ELISA）和侧向流动免疫检测分析等免疫检测检测方法分别在高通量筛检和分散式快速检测中发挥重要作用；微生物培养仍然是生物分离的参考方法，与传统的手工培养相比，自动化培养系统提高了周转时间和重复性。分子诊断包括成熟的聚合酵素链锁反应（PCR）工作流程和恒温环型核酸扩增）等等温扩增技术，这些技术因其更快更便捷的核酸检测而日益普及；而次世代定序）和桑格定序等定序技术则在监测、抗药性分析和研究应用中发挥着补充作用。

就样本类型而言，血液检测可提供血清学结果和系统性标记物，而鼻咽拭子是呼吸道病原体检测的主要检体，其采集和处理流程已较为成熟。唾液是一种极具吸引力的非侵入性替代方案，可降低采集风险并提高患者接受度，而痰液对于下呼吸道感染疾病仍然十分重要，因为病原体载量和检体质量会影响诊断率。检测模式分为两类：一类是实验室平台，其优先考虑多重检测的深度和灵敏度；另一类是即时检测系统，其强调速度、易用性和分散式访问，这导致了不同的应用驱动因素和报销模式。

冠状病毒疾病诊断推动了对快速多重检测和基因组监测的投资；流感诊断受益于季节性防治週期和抗病毒药物管理计划；呼吸道融合细胞病毒检测在儿科和老年护理路径中的作用日益受到重视。最后，终端使用者细分显示，诊所和医院正在寻求适合临床决策的整合工作流程和符合监管要求的平台；居家医疗机构正在寻求简化易用的仪器和清晰的结果解读；而研究实验室则优先考虑灵活性、通量和深度分析能力，以进行探索性和检验研究。

区域监管差异、基础设施成熟度和製造能力将如何决定全球市场的采用模式和商业策略

区域动态对诊断创新、应用和商业化策略有显着影响。在美洲，完善的检测基础设施、集中的公共卫生网路和庞大的私人医疗保健系统为高通量检测平台和即时检测解决方案的快速普及提供了支援。该地区的监管事务着重于临床表现和品质体系，而报销体系则奖励那些能够显着改善临床决策并降低后续成本的诊断方法。

在欧洲、中东和非洲，医疗服务体系和监管成熟度的差异导致了检测技术应用环境的多样性。该地区的高所得市场往往率先采用先进的分子检测和定序，而新兴市场则优先考虑成本效益高的快速检测方法和维护成本低的设备。跨境公共卫生协调和区域采购机制可以放大对标准化检测的需求，製造商也经常根据不同的基础设施和物流调整其检测产品。

亚太市场涵盖了各种不同的市场能力，既有先进、创新主导、拥有强大国内製造业和快速监管审批能力的市场，也有资源匮乏、优先考虑价格可负担性和供应安全的市场。在一些国家，国内製造业能力支撑着具有竞争力的价格和较短的前置作业时间週期，而公共卫生优先事项和庞大的人口基数则推动了对监测和可扩展诊断部署的投资。在每个地区，互通性、低温运输物流和与当地监管机构的合作都是成功实现商业化的关键要素。

呼吸诊断领域领导地位的形成，以及商业性优势能否持续，取决于竞争、协作和营运等因素。

呼吸系统诊断领域的竞争格局正因技术差异化、策略伙伴关係和规模化三者共同作用而重塑。投资于整合解决方案的公司，若能将灵敏的检测化学技术与无缝的仪器设计和直觉的软体介面相结合，将在临床应用方面占据优势。同时，诊断试剂开发商、仪器製造商和契约製造製造商之间的合作，能够在保持检测方法开发和品管方面专业技术的同时，实现快速扩大生产规模。

除了垂直整合的趋势外，围绕检测化学、试剂盒设计和云端基础分析的智慧财产权对国防领域的重要性也日益凸显。能够开发出展现临床效用和卫生经济价值的可靠证据包的公司，可以加强与医院和支付方的合作关係。包含远端监测、试剂补充和运作保证在内的服务模式，能够带来持续的收入来源，并深化客户关係。最后，与公共卫生机构和医院网路进行策略合作、试点监测计画以及整合倡议，能够使公司在常规季节性疫情和突发事件应变中都成为值得信赖的合作伙伴。

诊断试剂开发人员和供应商可以实施哪些切实可行的策略措施和营运重点，以增强呼吸系统检测的韧性、普及率和长期发展？

产业领导者应采取一系列策略行动，以平衡短期韧性和长期创新。首先，透过对关键试剂和耗材的多家供应商进行资格认证，实现供应链多元化；并在经济可行的情况下投资本地生产能力，以降低关税和物流成本。其次，优先考虑模组化平台设计，以便在不更换整台仪器的情况下进行检测升级；并投资于试剂盒和耗材的标准化，以简化采购流程。

第三，我们将从研发初期就加强与监管机构和支付方的合作，以累积证据，并与临床决策阈值和报销标准保持一致。第四，我们将加快与临床网路和公共卫生组织的合作，以检验产品在实际应用中的效能，并获得早期用户的认可，从而支持规模化生产。第五，我们将拓展数位化能力，例如云端基础的彙报、远端设备监控和人工智慧驱动的结果解读，以增强差异化优势，并提供能够支撑更高价格分布的附加价值服务。最后，我们将保持严谨的情境规划，并对我们的产能和销售模式进行压力测试，以确保在面对价格波动、需求激增和其他干扰因素时，业务永续营运。

采用严谨的混合方法，整合同侪审查的证据、监管指南和相关人员访谈，以检验诊断市场和商业洞察。

本报告的研究结合了结构化的二手资料研究和重点突出的一手资料研究，以确保得出平衡且有效的结论。二级资讯来源包括同行评审文献、监管指导文件、临床实践指南和开放原始码政策分析，旨在建立事实基础，并将技术能力与已知的法律规范相匹配。这些资讯来源为关于技术采纳驱动因素、临床效用以及区域监管差异的初步假设提供了基础。

主要研究包括对相关人员的访谈，包括临床实验室技术人员、感染疾病专家、采购负责人、生产专家和监管专家。这些访谈的见解用于检验次要研究结果，揭示营运方面的限制因素，例如供应链脆弱性和劳动力不足，并了解从业人员对速度、灵敏度和成本之间权衡的观点。数据综合采用了跨资讯来源的三角验证和迭代检验，以确保尽可能在结论中体现共识，并将分歧领域透明地报告出来。调查方法的限制包括政策和关税环境的变化，以及供应商特定数据的差异。

综合各项可操作的结论，强调呼吸系统诊断领域取得持久成功所需的韧性、主导应用和策略合作。

越来越多的分析表明，呼吸道感染疾病诊断正进入一个以技术融合、对快速、可操作结果的期望不断提高以及供应链日益复杂为特征的阶段。那些在平台设计和筹资策略都优先考虑灵活性的相关人员，将更有可能应对关税相关的成本压力和不断变化的采购重点。同时，对数据整合和证据产生的投资对于说服临床医生和支付方认识到诊断的价值至关重要，并能使他们在治疗决策和公共卫生监测中发挥核心作用。

总之，实现持续商业性成功的关键在于将强大的检测性能、营运韧性、监管前瞻性以及清晰的临床效用价值相结合。能够协调产品开发与终端用户工作流程、儘早与监管机构和支付相关人员沟通并建立适应性强的供应链的倡议，不仅能够更好地抵御短期衝击，还能充分利用市场对快速、可靠的呼吸系统诊断日益增长的需求。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩展多重PCR平台以实现多种呼吸道病原体的同时检测
  • 加强云端基础的数据分析在呼吸道感染疾病疫情即时监测的应用
  • 基于 CRISPR 的诊断技术能够在临床环境中实现对呼吸道病毒的超灵敏检测。
  • 在呼吸道疾病流行季节，用于区分新冠病毒、流感和呼吸道融合病毒（RSV）的多重抗原检测的需求增加。
  • 利用可携式等温扩增技术和横向流动化验方法推进分散式检查倡议
  • 重点研究并开发宿主生物标记检测方法，以区分严重呼吸道疾病治疗中的细菌合併感染。
  • 采用次世代定序工作流程进行全面的呼吸道病原体分析和突变监测
  • 诊断公司与远端医疗平台建立策略伙伴关係，以扩大远距呼吸道传染病检查服务
  • 监管部门的核准加速了新型即时分子检测技术进入市场，该技术可快速识别呼吸道病毒。
  • 投资人工智慧驱动的模式识别工具，以根据诊断和临床数据预测呼吸道感染疾病趋势。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按技术分類的呼吸道感染疾病诊断市场

  • 免疫检测
    • 酵素结合免疫吸附试验
    • 侧向流动免疫检测
  • 微生物培养
    • 自动化培养系统
    • 传统文化
  • 分子诊断
    • 环介导等温扩增
    • 聚合酵素链锁反应
  • 定序
    • 次世代定序
    • 桑格定序

9. 呼吸道感染疾病诊断市场（依样本类型划分）

  • 血
  • 鼻拭子
  • 唾液
  • 痰
  • 咽拭子

第十章 呼吸道感染疾病诊断市场：检测模式

  • 实验室
  • POC

第十一章 依感染类型分類的呼吸道感染疾病诊断市场

  • 2019冠状病毒感染疾病
  • 流感
  • 呼吸道融合病毒（RSV）

第十二章 依最终用户分類的呼吸道感染疾病诊断市场

  • 诊所
  • 居家照护
  • 医院
  • 研究所

第十三章 各地区呼吸道感染疾病诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 呼吸道感染疾病诊断市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国呼吸道感染疾病诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche AG
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Siemens Healthineers AG
    • bioMerieux SA
    • Hologic Inc.
    • QIAGEN NV
    • Quidel Corporation
    • Becton, Dickinson and Company
Product Code: MRR-02026C4C8612

The Respiratory Infection Diagnostics Market is projected to grow by USD 145.44 billion at a CAGR of 7.36% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 82.35 billion
Estimated Year [2025] USD 88.38 billion
Forecast Year [2032] USD 145.44 billion
CAGR (%) 7.36%

A concise primer on how clinical pressures, technological advances, and care pathway shifts are redefining respiratory infection diagnostic priorities

Respiratory infection diagnostics occupy a central role at the intersection of clinical care, public health, and laboratory innovation. Advances in molecular detection, point-of-care instrumentation, and data integration have accelerated diagnostic turnaround times and expanded testing beyond centralized laboratories into hospitals, clinics, and home care settings. Simultaneously, heightened awareness of disease surveillance following recent pandemic events has pushed payers, providers, and public health agencies to reassess diagnostic pathways and their role in outbreak preparedness and routine care.

Clinicians increasingly demand diagnostics that deliver actionable results within clinically relevant windows, while laboratorians prioritize automation and reproducibility to manage fluctuating test volumes. Manufacturers and solution providers are responding with integrated platforms, modular consumables, and software-enabled workflows that bridge the gap between laboratory accuracy and point-of-care accessibility. Consequently, strategic stakeholders must navigate evolving regulatory frameworks, supply chain pressures, and shifting reimbursement expectations to translate technical capability into sustained clinical adoption.

How converging technological, regulatory, and digital trends are accelerating the maturation and clinical integration of respiratory infection diagnostic solutions

The respiratory diagnostics landscape is experiencing multiple transformative shifts that are reshaping product development, procurement strategies, and clinical workflows. Molecular methods have matured from high-complexity laboratory assays to streamlined, near-patient platforms that reduce time-to-result and enhance pathogen-specific management. At the same time, sequencing technologies have transitioned from specialized research tools into actionable clinical assets, enabling lineage identification and resistance surveillance that inform treatment and public health responses.

Automation and integrated sample-to-answer systems are reducing operator dependence and supporting scalable throughput in hospital laboratories, whereas lateral flow immunoassays and other rapid formats continue to expand accessibility for decentralized testing. AI-driven interpretation and cloud-enabled data aggregation are beginning to connect test results with epidemiologic intelligence, facilitating earlier detection of emerging clusters. Regulatory bodies have also evolved, increasingly accommodating emergency use pathways and accelerated review mechanisms while emphasizing post-market performance monitoring. Together, these shifts are creating a multi-modal diagnostic ecosystem where interoperability, data integrity, and supply resilience determine commercial success.

Assessment of how new tariff structures reshape supply chains, drive sourcing strategies, and influence procurement behavior across diagnostic manufacturers and providers

The introduction of cumulative United States tariffs in 2025 introduces a complex set of pressures that affect both upstream manufacturing and downstream clinical delivery of respiratory diagnostics. Increased duties on imported components and finished instruments can elevate per-unit costs for manufacturers that rely on global supply chains for critical reagents, plasticware, cartridges, and precision instrument parts. These cost pressures may compress manufacturer margins, prompt renegotiation of supplier contracts, and incentivize redesigns that prioritize domestic sourcing or component standardization to mitigate tariff exposure.

For clinical laboratories and point-of-care operators, tariff-driven cost increases can manifest as higher acquisition prices for instruments and recurring expenditures for consumables. In response, procurement teams may extend device replacement cycles, consolidate suppliers, or prioritize multiplexed assays that reduce per-diagnosis consumable consumption. Simultaneously, some manufacturers may accelerate strategic moves to localize manufacturing or qualify alternative suppliers, a process that improves supply resilience but can lengthen time-to-market due to qualification and regulatory validation requirements.

Policy-induced shifts also influence capital allocation decisions among diagnostic developers. Investors and corporate decision-makers may reassess manufacturing footprints and consider co-investment models with contract manufacturers to spread tariff exposure. Public-sector purchasers and hospital networks could use buying power to negotiate tiered pricing or long-term supply agreements that stabilize downstream costs. Ultimately, the tariff environment reinforces the importance of supply chain transparency, component traceability, and agile sourcing strategies that balance near-term cost impacts with long-term reliability and clinical continuity.

Detailed segmentation insights revealing how technology, sample type, test mode, infection focus, and end-user dynamics uniquely shape product demand and adoption pathways

A granular view of the market segmentation highlights how distinct technologies and use contexts are driving differential adoption and innovation. Based on technology, immunoassay formats such as enzyme linked immunosorbent assays and lateral flow immunoassays remain crucial for high-throughput screening and decentralized rapid testing respectively, whereas microbiological culture methods continue to serve as the reference for organism isolation with automated culture systems improving turnaround and reproducibility compared with conventional manual culture. Molecular diagnostics encompass established polymerase chain reaction workflows and isothermal approaches such as loop mediated isothermal amplification that are gaining traction for faster, simpler nucleic acid detection, while sequencing techniques including next generation sequencing and Sanger sequencing offer complementary roles in surveillance, resistance profiling, and research applications.

When considering sample types, blood-based assays provide serologic insight and systemic markers, nasal swabs and throat swabs are primary specimen types for respiratory pathogen detection with well-established collection and handling workflows, saliva presents an attractive non-invasive alternative that reduces collection risk and improves patient acceptance, and sputum remains important for lower respiratory infections where pathogen load and specimen quality affect diagnostic yield. Test modes separate laboratory-based platforms that prioritize depth of multiplexing and sensitivity from point-of-care systems that emphasize speed, ease of use, and decentralized access, creating different adoption drivers and reimbursement models.

Infection type segmentation emphasizes that solutions tailored to coronavirus disease, influenza, and respiratory syncytial virus each face unique clinical prioritization; coronavirus disease diagnostics have driven investment in rapid multiplexing and genomic surveillance, influenza diagnostics benefit from seasonal preparedness cycles and antiviral stewardship programs, and respiratory syncytial virus testing is increasingly recognized for its role in pediatric and geriatric care pathways. Finally, end-user segmentation shows that clinics and hospitals demand integrated workflows and regulatory-compliant platforms suited to clinical decision-making, home care settings require simplified, user-friendly devices and clear result interpretation, and research laboratories prioritize flexibility, throughput, and deep analytical capabilities for exploratory and validation studies.

How regional regulatory diversity, infrastructure maturity, and manufacturing capacity drive divergent adoption patterns and commercial strategies across global markets

Regional dynamics exert a powerful influence on diagnostic innovation, adoption, and commercialization strategies. In the Americas, robust laboratory infrastructure, centralized public health networks, and large private healthcare systems support rapid uptake of both high-throughput laboratory platforms and point-of-care solutions. Regulatory pathways in this region emphasize clinical performance and quality systems, and reimbursement dynamics can reward diagnostics that demonstrably improve clinical decision-making and reduce downstream costs.

Across Europe, the Middle East, and Africa, heterogeneity in healthcare delivery and regulatory maturity creates a patchwork of adoption environments. High-income markets within the region often lead in advanced molecular and sequencing adoption, while emerging markets prioritize cost-effective rapid tests and instruments with low maintenance requirements. Cross-border public health coordination and regional procurement mechanisms can amplify demand for standardized assays, and manufacturers often tailor offerings to meet diverse infrastructure and logistics constraints.

Asia-Pacific markets demonstrate a spectrum of capability from advanced, innovation-driven markets with strong domestic manufacturing and rapid regulatory review to lower-resource settings that value affordability and supply stability. Domestic manufacturing capacity in several countries supports competitive pricing and shorter lead times, while public health priorities and large population bases drive investment in surveillance and scalable diagnostics deployment. Across regions, interoperability, cold chain logistics, and local regulatory engagement remain critical determinants of successful commercialization.

Competitive, collaborative, and operational forces that define leadership in the respiratory diagnostics sector and determine the durability of commercial advantage

Competitive landscapes in respiratory diagnostics are being reshaped by a combination of technological differentiation, strategic partnerships, and operational scale. Companies that invest in integrated solutions that combine sensitive detection chemistries with seamless instrument design and intuitive software interfaces gain advantages in clinical adoption. Meanwhile, alliances between diagnostic developers, instrument manufacturers, and contract manufacturers enable faster scale-up of production while preserving specialized expertise in assay development and quality control.

In addition to vertical integration moves, intellectual property around assay chemistries, cartridge designs, and cloud-based analytics is increasingly important for defensibility. Firms that develop robust evidence packages demonstrating clinical utility and health-economic value secure stronger hospital and payer engagement. Service models that include remote monitoring, reagent replenishment, and uptime guarantees create recurring revenue streams and deepen client relationships. Finally, strategic collaborations with public health agencies and hospital networks to pilot surveillance initiatives and integrate reporting can position companies as trusted partners during both routine seasons and outbreak response scenarios.

Practical strategic measures and operational priorities that diagnostic developers and providers can implement to strengthen resilience, adoption, and long-term growth in respiratory testing

Industry leaders should adopt a portfolio of strategic actions that balance near-term resilience with long-term innovation. First, diversify supply chains by qualifying multiple suppliers for critical reagents and consumables and by investing in localized manufacturing capacity where economically feasible to reduce tariff and logistics exposure. Second, prioritize modular platform designs that allow assay updates without full instrument replacement and invest in cartridge or consumable standardization to simplify procurement for buyers.

Third, strengthen regulatory and payer engagement early in development to align evidence generation with clinical decision thresholds and reimbursement criteria. Fourth, accelerate partnerships with clinical networks and public health entities to validate real-world performance and to secure early-adopter references that support scale-up. Fifth, expand digital capabilities, including cloud-based reporting, remote device monitoring, and AI-enabled result interpretation, to enhance differentiation and to provide value-added services that justify higher price points. Finally, maintain disciplined scenario planning and stress-testing of capacity and distribution models to ensure operational continuity under tariff shifts, demand surges, and other disruptions.

A rigorous mixed-methods approach that integrates peer-reviewed evidence, regulatory guidance, and stakeholder interviews to validate diagnostic market and operational insights

The research underlying this report combines structured secondary research with targeted primary engagement to ensure balanced, validated insight. Secondary sources included peer-reviewed literature, regulatory guidance documents, clinical practice guidelines, and open-source policy analyses to create a foundation of factual context and to map technological capabilities and known regulatory frameworks. These sources informed initial hypotheses concerning technology adoption drivers, clinical utility, and regional regulatory variation.

Primary research consisted of interviews with a cross-section of stakeholders including clinical laboratorians, infectious disease specialists, procurement leaders, manufacturing experts, and regulatory professionals. Insights from these conversations were used to validate secondary findings, to surface operational constraints such as supply chain fragility and workforce limitations, and to capture practitioner perspectives on trade-offs between speed, sensitivity, and cost. Data synthesis incorporated triangulation across sources and iterative validation to ensure that conclusions reflect consensus where possible and transparently report areas of divergence. Limitations of the methodology include the evolving nature of policy and tariff environments and the variability of proprietary supplier data; readers are advised to consider these dynamics when applying findings to specific commercial decisions.

Synthesis of actionable conclusions emphasizing resilience, evidence-driven adoption, and the strategic alignment required for enduring success in respiratory diagnostics

The cumulative analysis underscores that respiratory infection diagnostics are entering a phase defined by technological convergence, heightened expectations for rapid actionable results, and increasing supply chain complexity. Stakeholders who prioritize flexibility-both in platform design and in sourcing strategies-will be better positioned to navigate tariff-related cost pressures and shifting procurement priorities. At the same time, investments in data integration and evidence generation will be pivotal for convincing clinicians and payers of diagnostic value and for enabling diagnostics to play a central role in therapeutic decision-making and public health surveillance.

In sum, the pathway to durable commercial success blends robust assay performance with operational resilience, regulatory foresight, and a clear articulation of clinical utility. Organizations that align product development with end-user workflows, engage early with regulatory and payer stakeholders, and build adaptable supply chains will not only withstand near-term disruptions but also capitalize on the growing demand for rapid, reliable respiratory diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of multiplex PCR platforms enabling simultaneous detection of multiple respiratory pathogens
  • 5.2. Increasing integration of cloud-based data analytics to monitor respiratory infection outbreaks in real time
  • 5.3. Emergence of CRISPR-based diagnostics for ultra-sensitive detection of emerging respiratory viruses at point of care
  • 5.4. Rising demand for multiplex antigen testing to differentiate between COVID-19 influenza and RSV during respiratory season
  • 5.5. Growth of decentralized testing initiatives driven by portable isothermal amplification technologies and lateral flow assays
  • 5.6. R&D focus on host biomarker assays to distinguish bacterial coinfections in severe respiratory disease management
  • 5.7. Adoption of next-generation sequencing workflows for comprehensive respiratory pathogen profiling and variant surveillance
  • 5.8. Strategic partnerships between diagnostic firms and telehealth platforms to expand remote respiratory infection testing services
  • 5.9. Regulatory approvals accelerating market entry of novel point-of-care molecular tests for rapid respiratory virus identification
  • 5.10. Investment in AI-powered pattern recognition tools to predict respiratory infection trends from diagnostic and clinical data

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Respiratory Infection Diagnostics Market, by Technology

  • 8.1. Immunoassay
    • 8.1.1. Enzyme Linked Immunosorbent Assay
    • 8.1.2. Lateral Flow Immunoassay
  • 8.2. Microbiological Culture
    • 8.2.1. Automated Culture Systems
    • 8.2.2. Conventional Culture
  • 8.3. Molecular Diagnostics
    • 8.3.1. Loop Mediated Isothermal Amplification
    • 8.3.2. Polymerase Chain Reaction
  • 8.4. Sequencing
    • 8.4.1. Next Generation Sequencing
    • 8.4.2. Sanger Sequencing

9. Respiratory Infection Diagnostics Market, by Sample Type

  • 9.1. Blood
  • 9.2. Nasal Swab
  • 9.3. Saliva
  • 9.4. Sputum
  • 9.5. Throat Swab

10. Respiratory Infection Diagnostics Market, by Test Mode

  • 10.1. Laboratory Based
  • 10.2. Point Of Care

11. Respiratory Infection Diagnostics Market, by Infection Type

  • 11.1. Coronavirus Disease
  • 11.2. Influenza
  • 11.3. Respiratory Syncytial Virus

12. Respiratory Infection Diagnostics Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care Settings
  • 12.3. Hospitals
  • 12.4. Research Laboratories

13. Respiratory Infection Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Respiratory Infection Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Respiratory Infection Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche AG
    • 16.3.2. Danaher Corporation
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. Abbott Laboratories
    • 16.3.5. Siemens Healthineers AG
    • 16.3.6. bioMerieux SA
    • 16.3.7. Hologic Inc.
    • 16.3.8. QIAGEN N.V.
    • 16.3.9. Quidel Corporation
    • 16.3.10. Becton, Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. RESPIRATORY INFECTION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. RESPIRATORY INFECTION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RESPIRATORY INFECTION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NASAL SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NASAL SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NASAL SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NASAL SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NASAL SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NASAL SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY THROAT SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY THROAT SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY THROAT SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY THROAT SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY THROAT SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY THROAT SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE RESPIRATORY INFECTION DIAGNOSTIC